365 results found
Martinez A, Lecuru F, Bizzarri N, et al., 2023, PARa-aOrtic LymphAdenectomy in locally advanced cervical cancer (PAROLA trial): a GINECO, ENGOT, and GCIG study., Int J Gynecol Cancer, Vol: 33, Pages: 293-298
BACKGROUND: Positron emission tomography/computed tomography (PET/CT) fails to detect approximately 25% of aortic lymph node metastasis in patients with PET/CT stage IIIC1 cervical cancer. Surgical staging could lead to treatment modification and to improved para-aortic and distant control. PRIMARY OBJECTIVES: To demonstrate if chemoradiation with tailored external beam radiation field based on surgical staging and pathologic examination of the para-aortic lymph node is associated with improved 3-year disease-free survival compared with patients staged with PET/CT staging only. STUDY HYPOTHESIS: Surgical staging followed by tailored chemoradiation will improve disease-free survival while avoiding unnecessary prophylactic extended-field chemoradiation in patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC1 cervical cancer. TRIAL DESIGN: This is an international multicenter, randomized, phase III study. Eligible patients will be randomized 1:1 between PET/CT staging followed by chemoradiation (control arm), or surgical staging followed by tailored chemo-radiation (experimental arm). Randomization will be stratified by tumor stage according to TNM classification, center, and adjuvant treatment. MAJOR INCLUSION/EXCLUSION CRITERIA: Main inclusion criteria are histologically proven PET/CT FIGO stage IIIC1 cervical cancer. Main exclusion criteria include unequivocal positive common iliac or para-aortic lymph node at pre-therapeutic imaging PET/CT. PRIMARY ENDPOINTS: The primary endpoint is disease-free survival defined as the time from randomization until first relapse (local, regional, or distant), or death from any cause. SAMPLE SIZE: 510 eligible patients ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS: The estimated date for completing accrual will be Q2 2027. The estimated date for presenting results will be Q4 2030. TRIAL REGISTRATION NUMBER: NCT05581121.
Burns EM, Quyn A, Lexicon Collaboration of UKPEN and the ACPGBI Advanced Cancer subcommittee, 2023, The 'Pelvic exenteration lexicon': Creating a common language for complex pelvic cancer surgery., Colorectal Dis
AIM: Pelvic exenteration surgery is an umbrella term for a multitude of operative techniques for locally advanced and recurrent pelvic malignancy. Currently, there is heterogeneity in the operative description that limits the interpretation of patient outcome and collaboration between units through standardized data collection. Our study aims to develop a consensus lexicon to describe the operative components of extended and exenteration pelvic surgery. METHOD: This study adopted a mixed-methods approach using semi-structured interviews, questionnaires, focus groups and validation exercises involving pelvic exenteration experts from centres in the UK. Qualitative data were collected, and descriptive statistics are presented. RESULTS: We identified eight headings with 32 subheadings that encompass all components of the extent of the potential surgery. The lexicon was validated by 15 UK specialists. A 'high-complexity pelvic exenteration' was defined as encompassing 'conventional pelvic exenteration' with the extension of surgery to remove bony structures or the structures in the pelvic sidewall. Pelvic sidewall structures include major vessels, sciatic nerves and/or bone. Bony structures include the sacrum and/or pubic bones. CONCLUSION: This pelvic exenteration lexicon will permit classification of the surgical approach used that will improve data synthesis, allow more accurate activity recording for audit and ultimately improved outcomes for patients.
Sundar S, Nordin A, Morrison J, et al., 2023, British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer, CANCERS, Vol: 15
Angeles MA, Boria F, Shushkevich AB, et al., 2022, Interviews conducted at the European Society of Gynaecological Oncology 2022 Congress: a ENYGO-IJGC Fellows initiative, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 33, Pages: 12-18, ISSN: 1048-891X
Kim SI, Kim JH, Lee S, et al., 2022, Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis, GYNECOLOGIC ONCOLOGY, Vol: 167, Pages: 547-556, ISSN: 0090-8258
- Author Web Link
- Citations: 1
Strojna AN, Kacperczyk-Bartnik J, Angeles MA, et al., 2022, ENYGO-IJGC scientific writing and publication course: 2021 meeting summary, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 32, Pages: 1599-1605, ISSN: 1048-891X
Yang Y, Li H, Fotopoulou C, et al., 2022, Toll-like receptor-targeted anti-tumor therapies: Advances and challenges, FRONTIERS IN IMMUNOLOGY, Vol: 13, ISSN: 1664-3224
Fotopoulou C, Khan T, Bracinik J, et al., 2022, Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study, AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, Vol: 227, ISSN: 0002-9378
- Author Web Link
- Citations: 4
Lago V, Segarra-Vidal B, Cappucio S, et al., 2022, OVA-LEAK: Prognostic score for colo-rectal anastomotic leakage in patients undergoing ovarian cancer surgery, GYNECOLOGIC ONCOLOGY, Vol: 167, Pages: 22-27, ISSN: 0090-8258
Sehouli J, Schneider S, Fotopoulou C, 2022, Peri-operative ovarian cancer guidelines: prehabilitation, enhanced recovery, post-operative ileus prevention, post-operative physiotherapy and mobilization, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 32, Pages: 1341-1343, ISSN: 1048-891X
Fotopoulou C, Fagotti A, Campbell J, et al., 2022, Peri-operative ovarian cancer guidelines: introduction, skin antisepsis, patient positioning, including retractors use and nutritional management, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 32, Pages: 1338-1340, ISSN: 1048-891X
Schneider S, Campbell J, Fotopoulou C, 2022, Peri-operative ovarian cancer guidelines: anesthesia, intra- and post-operative volume and replacement, post-operative pain management, frailty scores/management of the fragile patient, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 32, Pages: 1483-1485, ISSN: 1048-891X
Fotopoulou C, Haidopoulos D, Trappe RU, 2022, Peri-operative ovarian cancer guidelines: major intra-operative and post-operative bleeding and thromboembolic events, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 32, Pages: 1621-1622, ISSN: 1048-891X
Hasenburg A, Sehouli J, Fotopoulou C, 2022, Peri-operative ovarian cancer guidelines: psycho-oncology, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 32, Pages: 1626-1628, ISSN: 1048-891X
Chiva L, Knapp P, Fotopoulou C, 2022, Perioperative ovarian cancer management: management of bowel related morbidity, prophylactic stoma formation, and stoma reversal, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 32, Pages: 1623-1625, ISSN: 1048-891X
Taskiran C, Knapp P, Fotopoulou C, 2022, Perioperative ovarian cancer guidelines: prevention and management of upper abdominal complications, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 32, Pages: 1486-1487, ISSN: 1048-891X
Cummins C, Kumar S, Long J, et al., 2022, Investigating the Impact of Ultra-Radical Surgery on Survival in Advanced Ovarian Cancer Using Population-Based Data in a Multicentre UK Study, CANCERS, Vol: 14
Gomez-Hidalgo NR, Pletnev A, Razumova Z, et al., 2022, European Enhanced Recovery After Surgery (ERAS) gynecologic oncology survey: Status of ERAS protocol implementation across Europe, INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, Vol: 160, Pages: 306-312, ISSN: 0020-7292
Montero-Macias R, Rigolet P, Mikhael E, et al., 2022, Traditional systemic treatment options in advanced low-grade serous ovarian cancer after successful cytoreduction: a systematic review and meta-analysis, Cancers, Vol: 14, Pages: 1-13, ISSN: 2072-6694
Objective: We performed a systematic literature review and a subsequent meta-analysis to compare traditional treatment options, i.e., antihormonal and cytotoxic, in LGSOC. Methods: We conducted a systematic literature review in MEDBASE and MEDLINE between September 2000 and June 2021 for women who received cytotoxic chemotherapy and/or antihormonal treatment after primary cytoreduction due to stage II–IV LGSOC and also at relapse. PFS and OS were calculated depending on the type of their adjuvant treatment. For each endpoint in the meta-analysis, pooled HR was calculated using the random effect model with the inverse variance weighted method. Only primary patients were included in the subsequent meta-analysis due to the small number of studies in the relapsed setting. Results: Five eligible first-line studies were included. Systemic chemotherapy failed to provide a significant OS benefit when compared to no systemic treatment (pooled HR = 1.01, 95% CI [0.79, 1.29]) after successful cytoreduction. Moreover, systemic chemotherapy followed by antihormonal treatment also did not result to a significant PFS or OS benefit when compared to systemic chemotherapy alone (for PSF: pooled HR = 0.59, 95% CI [0.33, 1.04]; for OS: pooled HR = 0.83, 95% CI [0.50, 1.39]). There were insufficient data from studies in the recurrent setting to allow their inclusion in the meta-analysis. Conclusions: In this meta-analysis, we failed to identify a traditional cytotoxic or antihormonal systemic treatment option that was associated with a significant OS or PFS benefit when administered following successful cytoreduction for advanced LGSOC. Prospective randomized studies are urgently warranted to define optimal adjuvant options in this challenging disease.
Bisbas TG, Walch S, Naab T, et al., 2022, The Origin of the [C ii] Deficit in a Simulated Dwarf Galaxy Merger-driven Starburst, Astrophysical Journal, Vol: 934, ISSN: 0004-637X
We present [C ii] synthetic observations of smoothed particle hydrodynamics (SPH) simulations of a dwarf galaxy merger. The merging process varies the star formation rate (SFR) by more than three orders of magnitude. Several star clusters are formed, the feedback of which disperses and unbinds the dense gas through expanding H ii regions and supernova (SN) explosions. For galaxies with properties similar to the modeled ones, we find that the [C ii] emission remains optically thin throughout the merging process. We identify the warm neutral medium ( 3 < log T gas < 4 with χ HI > 2χ H2) to be the primary source of [C ii] emission (∼58% contribution), although at stages when the H ii regions are young and dense (during star cluster formation or SNe in the form of ionized bubbles), they can contribute ≳50% to the total [C ii] emission. We find that the [C ii]/far-IR (FIR) ratio decreases owing to thermal saturation of the [C ii] emission caused by strong far-UV radiation fields emitted by the massive star clusters, leading to a [C ii] deficit medium. We investigate the [C ii]−SFR relation and find an approximately linear correlation that agrees well with observations, particularly those from the Dwarf Galaxy Survey. Our simulation reproduces the observed trends of [C ii]/FIR versus ΣSFR and ΣFIR, and it agrees well with the Kennicutt relation of SFR−FIR luminosity. We propose that local peaks of [C ii] in resolved observations may provide evidence for ongoing massive cluster formation.
Nguyen-Strauli BD, Baum J, Meyer-Wilmes P, et al., 2022, Survey on implementation of molecular testing in ovarian cancer and PARP inhibitor: a national North-Eastern German Society of Gynecologic Oncology/Young Academy of Gynecologic Oncology/Arbeitsgemeinschaft Gynakologische Onkologie intergroup analysis, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 32, Pages: 1297-1302, ISSN: 1048-891X
Keunecke C, Kulbe H, Dreher F, et al., 2022, Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer, GYNECOLOGIC ONCOLOGY, Vol: 166, Pages: 334-343, ISSN: 0090-8258
- Author Web Link
- Citations: 2
Wulandari R, Nixon K, Rama N, et al., 2022, Characterisation of Proteomic heterogeneity following platinum therapy in High-grade Serous Ovarian Cancer, Publisher: WILEY, Pages: 40-41, ISSN: 1470-0328
Ghisoni E, Benedetti F, Cunnea P, et al., 2022, Integrated digital pathology and single-cell analysis identify the spatial and temporal evolution of immune cells networks in epithelial ovarian cancer, ESMO Gynaecological Cancers Congress, Publisher: ELSEVIER, Pages: S395-S395, ISSN: 0923-7534
Baek M-H, Park EY, Ha HI, et al., 2022, Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer: a meta-analysis, Journal of Clinical Oncology, Vol: 40, Pages: 1659-1670, ISSN: 0732-183X
PURPOSEThe survival impact of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer was studied.METHODSWe identified published studies from 1983 to 2021 following our inclusion criteria from MEDLINE, EMBASE, and Cochrane library. To integrate the effect size of single-arm studies, meta-analysis was performed using death rate as a primary outcome. The effect of complete cytoreduction and optimal cytoreduction on survival was evaluated using meta-regression. The pooled death rate was presented with a 95% CI. The publication bias was evaluated with the funnel plot and Egger's test, and sensitivity analysis was performed. To overcome missing death rates, the linear regression model was performed on log-transformed median overall survival (OS) time using study size as a weight.RESULTSThirty-six studies with 2,805 patients reporting death rates were used for this meta-analysis of the 80 eligible studies. There was strong heterogeneity, with the P value of the Cochrane Q test of < 0.0001 and Higgins's I2 statistics of 86%; thus, we considered a random effect model. The pooled death rate was 44.2% (95% CI, 39.0 to 49.5), and both the complete and optimal cytoreductions were associated with better survival outcomes as significant moderators in the meta-regression model (P < .001 and P = .005, respectively). Although 14 studies were located outside the funnel plot, Egger's test indicated no publication bias (P = .327). A sensitivity analysis excluding 14 studies showed similar results. In the linear regression model on the basis of 57 studies, the median OS time increased by 8.97% and 7.04% when the complete and optimal cytoreduction proportion increased by 10%, respectively, after adjusting other variables.CONCLUSIONSecondary cytoreductive surgery, resulting in maximal tumor resection, significantly prolongs OS in platinum-sensitive recurrent ovarian cancer.
Adamina M, Ademuyiwa A, Adisa A, et al., 2022, The impact of surgical delay on resectability of colorectal cancer: An international prospective cohort study, Colorectal Disease, Vol: 24, Pages: 708-726, ISSN: 1462-8910
AimThe SARS-CoV-2 pandemic has provided a unique opportunity to explore the impact of surgical delays on cancer resectability. This study aimed to compare resectability for colorectal cancer patients undergoing delayed versus non-delayed surgery.MethodsThis was an international prospective cohort study of consecutive colorectal cancer patients with a decision for curative surgery (January–April 2020). Surgical delay was defined as an operation taking place more than 4 weeks after treatment decision, in a patient who did not receive neoadjuvant therapy. A subgroup analysis explored the effects of delay in elective patients only. The impact of longer delays was explored in a sensitivity analysis. The primary outcome was complete resection, defined as curative resection with an R0 margin.ResultsOverall, 5453 patients from 304 hospitals in 47 countries were included, of whom 6.6% (358/5453) did not receive their planned operation. Of the 4304 operated patients without neoadjuvant therapy, 40.5% (1744/4304) were delayed beyond 4 weeks. Delayed patients were more likely to be older, men, more comorbid, have higher body mass index and have rectal cancer and early stage disease. Delayed patients had higher unadjusted rates of complete resection (93.7% vs. 91.9%, P = 0.032) and lower rates of emergency surgery (4.5% vs. 22.5%, P < 0.001). After adjustment, delay was not associated with a lower rate of complete resection (OR 1.18, 95% CI 0.90–1.55, P = 0.224), which was consistent in elective patients only (OR 0.94, 95% CI 0.69–1.27, P = 0.672). Longer delays were not associated with poorer outcomes.ConclusionOne in 15 colorectal cancer patients did not receive their planned operation during the first wave of COVID-19. Surgical delay did not appear to compromise resectability, raising the hypothesis that any reduction in long-term survival attributable to delays is likely to be due to micro-metastatic disease.
Altmann J, Chekerov R, Fotopoulou C, et al., 2022, Ten years of live surgical broadcast at Charite-MAYO conferences (2010-2019): a systematic evaluation of the surgical outcome, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 32, Pages: 746-752, ISSN: 1048-891X
Fotopoulou C, 2022, Closing the gender gap in gynecological oncology publications: will men manage to keep up?, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 32, Pages: 590-591, ISSN: 1048-891X
Clark J, Fotopoulou C, Cunnea P, et al., 2022, Novel ex vivo models of epithelial ovarian cancer: the future of biomarker and therapeutic research, Frontiers in Oncology, Vol: 12, Pages: 1-17, ISSN: 2234-943X
Epithelial ovarian cancer (EOC) is a heterogenous disease associated with variations in presentation, pathology and prognosis. Advanced EOC is typified by frequent relapse and a historical 5-year survival of less than 30% despite improvements in surgical and systemic treatment. The advent of next generation sequencing has led to notable advances in the field of personalised medicine for many cancer types. Success in achieving cure in advanced EOC has however been limited, although significant prolongation of survival has been demonstrated. Development of novel research platforms is therefore necessary to address the rapidly advancing field of early diagnostics and therapeutics, whilst also acknowledging the significant tumour heterogeneity associated with EOC. Within available tumour models, patient-derived organoids (PDO) and explant tumour slices have demonstrated particular promise as novel ex vivo systems to model different cancer types including ovarian cancer. PDOs are organ specific 3D tumour cultures that can accurately represent the histology and genomics of their native tumour, as well as offer the possibility as models for pharmaceutical drug testing platforms, offering timing advantages and potential use as prospective personalised models to guide clinical decision-making. Such applications could maximise the benefit of drug treatments to patients on an individual level whilst minimising use of less effective, yet toxic, therapies. PDOs are likely to play a greater role in both academic research and drug development in the future and have the potential to revolutionise future patient treatment and clinical trial pathways. Similarly, ex vivo tumour slices or explants have also shown recent renewed promise in their ability to provide a fast, specific, platform for drug testing that accurately represents in vivo tumour response. Tumour explants retain tissue architecture, and thus incorporate the majority of tumour microenvironment making them an attractive
Taylor A, Sundar SS, Bowen R, et al., 2022, British Gynaecological Cancer Society Recommendations for Women With Gynecological Cancer Who Received Non-standard Care During the COVID-19 Pandemic, OBSTETRICAL & GYNECOLOGICAL SURVEY, Vol: 77, Pages: 156-157, ISSN: 0029-7828
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.